Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2828 in Type 2 Diabetes
NCT07089784Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-2828 with Placebo (2 arms). Primary endpoints: Number of Participants Who Experience an Adverse Event at 42 days and Number of Participants Who Discontinue Study Treatment Due to an Adverse Event at 28 days. Started Sep 2025; status: completed.
02
Drugs
MK-2828
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07089784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089784.